Ask AI
Bill115th CongressFiled Apr 24, 2018Health
H.R. 5605

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary passed house amended (Jun 19, 2018)

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures.

Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants.

(Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.

What just happenedJun 20, 2018

Received in the Senate and Read twice and referred to the Committee on Finance.

Who’s behind it

Rep. Ruiz, Raul [D-CA-36](D-CA)Sponsor
2 cosponsors2 R
Read on Congress.gov
2cosponsors3committees20actions3related bills15subjects
  1. Jun 20, 2018IntroReferral

    Received in the Senate and Read twice and referred to the Committee on Finance.

    Finance Committee
  2. Jun 19, 2018FloorH38800

    The title of the measure was amended. Agreed to without objection.

  3. Jun 19, 2018FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  4. Jun 19, 2018FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)

  5. Jun 19, 2018Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)

  6. Jun 19, 2018FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.

  7. Jun 19, 2018FloorH30000

    Considered under suspension of the rules. (consideration: CR H5239-5243)

  8. Jun 19, 2018FloorH30300

    Mr. Walden moved to suspend the rules and pass the bill, as amended.

  9. Jun 12, 2018CalendarsH12410

    Placed on the Union Calendar, Calendar No. 578.

  10. Jun 12, 2018DischargeH12300

    Committee on Ways and Means discharged.

    Ways and Means Committee
  11. Jun 12, 2018Committee5500

    Committee on Ways and Means discharged.

    Ways and Means Committee
  12. Jun 12, 2018CommitteeH12200

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.

    Energy and Commerce Committee
  13. Jun 12, 2018Committee5000

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.

    Energy and Commerce Committee
  14. May 17, 2018Committee

    Ordered to be Reported (Amended) by Voice Vote.

    Energy and Commerce Committee
  15. May 17, 2018Committee

    Committee Consideration and Mark-up Session Held.

    Energy and Commerce Committee
  16. May 1, 2018Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  17. Apr 24, 2018IntroReferralH11100

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Ways and Means Committee
  18. Apr 24, 2018IntroReferralH11100

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Energy and Commerce Committee
  19. Apr 24, 2018IntroReferralIntro-H

    Introduced in House

  20. Apr 24, 2018IntroReferral1000

    Introduced in House

Passed House amendedJun 19, 201836

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures.

Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants.

(Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.

Reported to House amended, Part IJun 12, 201818

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures.

Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants.


Introduced in HouseApr 24, 2018

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access of opioid use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures.

Opioid use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participating teams.

The CMS must adopt or develop program quality standards and performance methods.

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act — Informed